Abbott (NYSE:ABT) announced today that it launched its new coronary imaging platform in Europe after receiving CE mark approval.
The platform, powered by Ultreon 1.0 software, merges optical coherence tomography (OCT) with AI to enhance visualization and detect the severity of calcium-based blockages and measure vessel diameter to enhance decision-making during coronary stenting procedures, according to a news release.
Abbott Park, Ill.–based Abbott’s OCT technology uses near-infrared light to offer high-definition, precise imaging from within a blood vessel, helping to improve the assessment of blockages in the vessels and optimize decisions related to stent selection, placement and deployment.
Ultreon software, when integrated with Abbott’s new Dragonfly OpStar imaging catheter, then allows physicians to capture information from even more complex patient anatomy.
Abbott plans to showcase the new Ultron software for the first time at the EuroPCR from May 18 to May 21 during the company’s “Tools and Technique Sessions.” The company also plans to pursue regulatory approval for the software in the U.S. and Japan.
“Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures,” Abbott CMO & divisional VP of global medical affairs at Abbott’s vascular business Dr. Nick West said in the release. “Ultreon software can potentially improve physician and patient experience by utilizing a systematic process, reducing variability and increasing accuracy of diagnosis and application of therapies.”